Esmirtazapine

A tetracyclic antidepressant

Esmirtazapine is a tetracyclic antidepressant (TeCA) that has been investigated for its potential use in the treatment of insomnia and hot flashes associated with menopause. It is the S-(+)-enantiomer of mirtazapine, which is a well-known antidepressant. Esmirtazapine is being developed by Organon International, a pharmaceutical company.

Pharmacology

Esmirtazapine acts primarily as an antagonist at the histamine H1 receptor, which contributes to its sedative effects. It also has affinity for the serotonin 5-HT2A receptor, the serotonin 5-HT2C receptor, and the alpha-2 adrenergic receptor. These interactions are thought to contribute to its potential antidepressant and anxiolytic effects.

Esmirtazapine 2D Structure

Clinical Development

Esmirtazapine has been studied in clinical trials for the treatment of insomnia and hot flashes. In these studies, it has shown efficacy in reducing the frequency and severity of hot flashes in menopausal women. Additionally, its sedative properties have been explored for the treatment of insomnia, where it has demonstrated the ability to improve sleep onset and maintenance.

Mechanism of Action

The mechanism of action of esmirtazapine is similar to that of mirtazapine, involving antagonism of central presynaptic alpha-2 adrenergic receptors, which results in increased release of norepinephrine and serotonin. The blockade of 5-HT2 and 5-HT3 receptors enhances serotonergic transmission, which is associated with its antidepressant effects. The antagonism of H1 receptors is responsible for its sedative properties.

Side Effects

Common side effects of esmirtazapine include drowsiness, dry mouth, weight gain, and dizziness. These side effects are similar to those observed with mirtazapine, due to their similar pharmacological profiles.

Related pages

• Mirtazapine
• Tetracyclic antidepressant
• Insomnia
• Menopause